Literature DB >> 33081534

Repurposing elesclomol, an investigational drug for the treatment of copper metabolism disorders.

Vishal M Gohil1.   

Abstract

Entities:  

Keywords:  Copper; Menkes disease; cytochrome c oxidase; elesclomol; mitochondria

Mesh：

Substances：

Year:  2020        PMID： 33081534      PMCID： PMC7855837          DOI： 10.1080/13543784.2021.1840550

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN： 1354-3784            Impact factor:   6.206


× No keyword cloud information.
  24 in total

1.  Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.

Authors:  Anna Berkenblit; Joseph P Eder; David P Ryan; Michael V Seiden; Noriaki Tatsuta; Matthew L Sherman; Thomas A Dahl; Bruce J Dezube; Jeffrey G Supko
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

Review 2.  Heavy metal toxicity: An update of chelating therapeutic strategies.

Authors:  Jong-Joo Kim; You-Sam Kim; Vijay Kumar
Journal:  J Trace Elem Med Biol       Date:  2019-05-10       Impact factor: 3.849

Review 3.  Oxygen toxicity, oxygen radicals, transition metals and disease.

Authors:  B Halliwell; J M Gutteridge
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

4.  The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.

Authors:  Masazumi Nagai; Nha H Vo; Luisa Shin Ogawa; Dinesh Chimmanamada; Takayo Inoue; John Chu; Britte C Beaudette-Zlatanova; Rongzhen Lu; Ronald K Blackman; James Barsoum; Keizo Koya; Yumiko Wada
Journal:  Free Radic Biol Med       Date:  2012-04-17       Impact factor: 7.376

5.  Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.

Authors:  Steven O'Day; Rene Gonzalez; David Lawson; Robert Weber; Laura Hutchins; Clay Anderson; Jonathan Haddad; Steven Kong; Anthony Williams; Eric Jacobson
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

6.  Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.

Authors:  Shoujun Chen; Lijun Sun; Keizo Koya; Noriaki Tatsuta; Zhiqiang Xia; Timothy Korbut; Zhenjian Du; Jim Wu; Guiqing Liang; Jun Jiang; Mitsunori Ono; Dan Zhou; Andrew Sonderfan
Journal:  Bioorg Med Chem Lett       Date:  2013-07-25       Impact factor: 2.823

7.  Role of copper in human neurological disorders.

Authors:  Vishal Desai; Stephen G Kaler
Journal:  Am J Clin Nutr       Date:  2008-09       Impact factor: 7.045

8.  Elesclomol induces cancer cell apoptosis through oxidative stress.

Authors:  Jessica R Kirshner; Suqin He; Vishwasenani Balasubramanyam; Jane Kepros; Chin-Yu Yang; Mei Zhang; Zhenjian Du; James Barsoum; John Bertin
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

9.  Neonatal diagnosis and treatment of Menkes disease.

Authors:  Stephen G Kaler; Courtney S Holmes; David S Goldstein; Jingrong Tang; Sarah C Godwin; Anthony Donsante; Clarissa J Liew; Susumu Sato; Nicholas Patronas
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

10.  Mitochondrial metabolism promotes adaptation to proteotoxic stress.

Authors:  Peter Tsvetkov; Alexandre Detappe; Kai Cai; Heather R Keys; Zarina Brune; Weiwen Ying; Prathapan Thiru; Mairead Reidy; Guillaume Kugener; Jordan Rossen; Mustafa Kocak; Nora Kory; Aviad Tsherniak; Sandro Santagata; Luke Whitesell; Irene M Ghobrial; John L Markley; Susan Lindquist; Todd R Golub
Journal:  Nat Chem Biol       Date:  2019-05-27       Impact factor: 15.040
View more
  3 in total

Review 1.  Connecting copper and cancer: from transition metal signalling to metalloplasia.

Authors:  Eva J Ge; Ashley I Bush; Angela Casini; Paul A Cobine; Justin R Cross; Gina M DeNicola; Q Ping Dou; Katherine J Franz; Vishal M Gohil; Sanjeev Gupta; Stephen G Kaler; Svetlana Lutsenko; Vivek Mittal; Michael J Petris; Roman Polishchuk; Martina Ralle; Michael L Schilsky; Nicholas K Tonks; Linda T Vahdat; Linda Van Aelst; Dan Xi; Peng Yuan; Donita C Brady; Christopher J Chang
Journal:  Nat Rev Cancer       Date:  2021-11-11       Impact factor: 69.800

Review 2.  Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.

Authors:  Peijie Zheng; Chuntao Zhou; Liuyi Lu; Bin Liu; Yuemin Ding
Journal:  J Exp Clin Cancer Res       Date:  2022-09-12

3.  Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth.

Authors:  Mauro Biffoni; Roberto Pallini; Lucia Ricci-Vitiani; Mariachiara Buccarelli; Quintino Giorgio D'Alessandris; Paola Matarrese; Cristiana Mollinari; Michele Signore; Andrea Cappannini; Maurizio Martini; Pierluigi D'Aliberti; Gabriele De Luca; Francesca Pedini; Alessandra Boe
Journal:  J Exp Clin Cancer Res       Date:  2021-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.